Fujian South Pharmaceutical Co., Ltd.--South Pharmaceutical|South Pharmaceutical Co., Ltd.

About Us

Fujian South Pharmaceutical Co., Ltd.

(FSP) was established in 2001, located in Mingxi County, Fujian Province, China. Today, FSP has become an important cGMP manufacturer for oncology APIs in China.
FSP cultivates 7,000 acres of Taxus Wallichiana (Taxus yunnanensis), and it is the largest commercial utilizing in China. FSP is the main supplier for natural Paclitaxel, semi-synthesis Paclitaxel, Docetaxel, 10-DAB III (Taxus Baccata and Taxus Wallichiana) in the world. FSP is a main supplier for Gemcitabine, Irinotecan and the patented technologies for Docetaxel, Imatinib, and Erloitnib, etc.
FSP is strong in R&D, with a pathbreaking team in Shanghai R&D Center. We hold 7 PCT patents and 33 China patents for processing of taxanes, tabines and tinibs...MORE >>

MORE >>Contact Us

Add. : Suite 2,No.868 Zhenchen Rd,Baoshan Dist,Shanghai,China.
Tel : +86-21-36162072
Fax : +86-21-36162076
Email : sales@southpharma.com
URL : www.southpharma.com

Products List

Taxane Series: Paclitaxel Natural/Semi-Synthetic; Docetaxel Anhydrous/Trihydrate; 10-Deacetyl Baccatin III, 10-DAB III; 2’-Ac-Docetaxel; Cephalomannine

Taxane Side Chains: (4S,5R)-3-Benzoyl-2-(4-methoxyphenyl)-4-phenyl-5-oxazolidinecarboxylic acid; (4S,5R)-3-tert-Butoxycarbony-2-(4-anisyl)-4-phenyl-5-oxazolidinecarboxylic acid; Methyl (2R,3S)-N-Boc-3-Phenylisoserine; Methyl (2R,3S)-N-Benzoyl-3-Phenylisoserine; (2R,3S)-2-acetoxy-3-(bis(tert-butoxycarbonyl)amino)-3-phenylpropionic acid

Taxane impurity standards: 10-Deacetyl Paclitaxel; Cephalomannine; Iso-cephalomannine; 7-epi-10-Deacetyl-Paclitaxel; Paclitaxel C

Tinib series: Imatinib mesilate; Imatinib Base; N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine; 4-[(4-Methylpiperazin-1-yl)methyl]benzoic acid dihydrochloride; 4-(4-Methyl-piperazin-1-ylmethyl)-benzoic acid methyl ester

Tabine series: Gemcitabine HCl; 2-Deoxy-2,2-difluoro-D-erythro-pentafuranous-1-ulose-3,5-dibenzoate (T6); 2-Deoxy-2,2-Difluoro-D-Ribofuranose-3,5-Dibenzoate(T7); 2-Deoxy-2,2-difluoro-D-erythro-pentofuranose-3,5-dibenzoate-1-methanesulfonate (T8); 2',2'-Difluoro-2'-deoxycytidine-3',5'-dibenzoate (T9)

Camptothecin Series: Irinotecan Hydrochloride Trihydrate; 7-Ethyl-10-hydroxycamptothecin (SN-38); Topotecan HCl; 10-Hydroxycamptothecin; 1-Chlorocarbonyl-4-piperidinoperidine

Other Oncology Series: Bortezomib; (1S,2S,3R,5S)-2,3-Pinanediol; Pemetrexed disodium; Letrozole; Anastrozole

Ophthalmic Series: Dorzolamide HCL; (±)5,6-Dihydro-4-oxo-6-methyl-4H-Thieno(2,3B)thiopyran-2-sulfonamide; Brimonidine Tartrate; 5-Aminolevulinic Acid HCL(5-ALA); 5-aminolevulinic acid

Other series: Aloe Emodin; Diacerein; Deferasirox; Tamsulosin HCl; Sitagliptin Phosphate

Under R&D: Aliskiren; Ticagrelor; Epothilone D; Epothilone E; Latanoprost

Note: All the above products are not offered for sale in countries and regions where the sale of such products constitutes a patent infringement, and liability for patent infringement is exclusively understood at buyer’s risk. Product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany,etc.